ClinicalTrials.gg
CompletedNCT02397694Updated Apr 7, 2020Results posted

Safety and Efficacy of Bictegravir + Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in HIV-1 Infected, Antiretroviral Treatment-Naive Adults

A Phase 2 interventional study of BIC and F/TAF in HIV-1 Infection, sponsored by Gilead Sciences. Completed at 21 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-04-07.

Sponsored by Gilead Sciences · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
98
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study will evaluate the efficacy, safety and tolerability of bictegravir (BIC) + emtricitabine/tenofovir alafenamide (F/TAF) fixed dose combination (FDC) versus dolutegravir (DTG) + F/TAF in HIV-1 Infected, antiretroviral treatment-naive adults. This study will also evaluate the pharmacokinetic (PK) profile of BIC, emtricitabine and TAF.

02

Conditions studied

  • HIV-1 Infection

Keywords

  • Adult
  • HIV
  • naive
03

In context

Lead sponsor

Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.

Of its 261 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Antiretroviral naive (≤ 10 days of prior therapy with any antiretroviral agent)
  • Plasma -1 RNA levels ≥ 1,000 copies/mL at screening
  • Screening genotype report provided by Gilead Sciences must show sensitivity to tenofovir (TFV) and emtricitabine (FTC)
  • Adequate renal function as measured by estimated ≥ 70 mL/min according to the formula
  • ≥ 200 cells/µL at screening

Key Exclusion Criteria:

  • A new AIDS-defining condition diagnosed within the 30 days prior to screening as defined in the study protocol
  • Prior use of antiretrovirals in the setting of pre-exposure prophylaxis (PrEP) or post exposure prophylaxis (PEP)
  • Chronic virus (HBV) infection
  • infection (Individuals who are hepatitis C virus (HCV) Ab positive, but have a documented negative HCV RNA, are eligible)
  • Active, serious infections (other than HIV-1 infection) requiring parenteral antibiotic or antifungal therapy within 30 days prior to baseline
  • Participation in any other clinical trial without prior approval from the sponsor is prohibited while participating in this trial

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
98 participants (actual)

Study arms

  • Experimental
    BIC + F/TAF

    Participants will receive BIC + F/TAF FDC + DTG placebo for 48 weeks. * Following Week 48, participants will continue to take their blinded treatment and attend visits every 12 weeks until treatment assignments have been unblinded. Participants will return for an unblinding visit and be given the option to participate in an open-label rollover extension and receive bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) until it becomes commercially available, or until Gilead Sciences elects to terminate the development of BIC/F/TAF.

    Drug: BIC · Drug: F/TAF · Drug: DTG Placebo · Drug: B/F/TAF

  • Active comparator
    DTG + F/TAF

    Participants will receive DTG + F/TAF FDC + BIC placebo for 48 weeks. * Following Week 48, participants will continue to take their blinded treatment and attend visits every 12 weeks until treatment assignments have been unblinded. Participants will return for an unblinding visit and be given the option to participate in an open-label rollover extension and receive B/F/TAF until it becomes commercially available, or until Gilead Sciences elects to terminate the development of BIC/F/TAF.

    Drug: F/TAF · Drug: DTG · Drug: BIC Placebo · Drug: B/F/TAF

  • Experimental
    Open Label Extension Phase

    After Week 48 participants continued to take their randomized study drug and attended visits every 12 weeks until treatment assignments were unblinded, at which point all participants returned for an unblinding visit and were given the option to participate in an open-label rollover extension to receive an FDC containing B/F/TAF.

    Drug: B/F/TAF

Interventions

  • DrugBIC

    75 mg tablet administered orally once daily

    Also known as: GS-9883

  • DrugF/TAF

    Drug pages: Emtricitabine · Tenofovir alafenamide

    200/25 mg FDC tablet administered orally once daily

  • DrugDTG

    50 mg tablet administered orally once daily

    Also known as: Tivicay®

  • DrugBIC Placebo

    Tablet administered orally once daily

  • DrugDTG Placebo

    Tablet administered orally once daily

  • DrugB/F/TAF

    Drug pages: Bictegravir · Emtricitabine · Tenofovir alafenamide

    50/200/25 mg FDC tablet administered orally once daily

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With HIV-1 RNA < 50 Copies/mL as Determined by the FDA-defined Snapshot Algorithm.

    The percentage of participants achieving HIV-1 RNA \< 50 copies/mL at Week 24 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.

    Time frame: Week 24

Secondary outcomes

  1. Percentage of Participants With HIV-1 RNA < 50 Copies/mL as Determined by the FDA-defined Snapshot Algorithm at Week 12

    The percentage of participants achieving HIV-1 RNA \< 50 copies/mL at Week 12 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.

    Time frame: Week 12

  2. Percentage of Participants With HIV-1 RNA < 50 Copies/mL as Determined by the FDA-defined Snapshot Algorithm at Week 48

    The percentage of participants achieving HIV-1 RNA \< 50 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.

    Time frame: Week 48

  3. The Change From Baseline in log10 HIV-1 RNA at Week 12

    Time frame: Baseline; Week 12

  4. The Change From Baseline in log10 HIV-1 RNA at Week 24

    Time frame: Baseline; Week 24

  5. The Change From Baseline in log10 HIV-1 RNA at Week 48

    Time frame: Baseline; Week 48

  6. The Change From Baseline in Cluster of Differentiation 4 Positive (CD4+) Cell Count at Week 12

    Time frame: Baseline; Week 12

  7. The Change From Baseline in CD4+ Cell Count at Week 24

    Time frame: Baseline; Week 24

  8. The Change From Baseline in CD4+ Cell Count at Week 48

    Time frame: Baseline; Week 48

  9. Percentage of Participants With Treatment Emergent Adverse Events (TEAEs) During Double-Blinded Randomized Phase

    Time frame: First dose date up to last dose (maximum duration: 58 Weeks) plus 30 days (During Double-Blinded Randomized Phase)

  10. Percentage of Participants With Treatment Emergent Laboratory Abnormalities During Double-Blind Randomized Phase

    Time frame: First dose date up to last dose (maximum duration: 58 Weeks) plus 30 days (During Double-Blinded Randomized Phase)

  11. PK Parameter: Cmax for Bictegravir (BIC), Emtricitabine (FTC), Tenofovir Alafenamide (TAF) and Tenofavir (TFV) at Steady-State

    Cmax is the maximum observed plasma concentration of the drug.

    Time frame: 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 24 hours postdose at Week 4 or 8

  12. PK Parameter: Tmax for BIC, FTC, TAF, and TFV at Steady-State

    Tmax was defined as the time to Cmax.

    Time frame: 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 24 hours postdose at Week 4 or 8

  13. PK Parameter:Ctau for BIC, FTC and TFV

    Ctau was defined as the observed drug concentration at the end of the dosing interval.

    Time frame: 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 24 hours postdose at Week 4 or 8

  14. PK Parameter: AUCtau for BIC, FTC, TAF, and TFV

    AUCtau is defined as the area under the concentration-time curve of the drug over time.

    Time frame: 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 24 hours postdose at Week 4 or 8

  15. PK Parameter: t1/2 of BIC, FTC, TAF, and TFV

    t1/2 was defined as the terminal elimination half-life of the drug

    Time frame: 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 24 hours postdose at Week 4 or 8

07

Results

Posted Mar 27, 2018

Participant flow

Participants were enrolled at 22 centers in the United States of America.The first participant was screened on 23 March 2015 and the last study visit occurred on 27 February 2019.

Double-Blinded Phase
Participant flow — Double-Blinded Phase
MilestoneBIC + F/TAFDTG + F/TAF
Started6533
Completed6230
Not completed33
Withdrew: Adverse event10
Withdrew: Non-compliance with study drug02
Withdrew: Withdrawal by subject10
Withdrew: Lost to follow-up11
Open Label Extension Phase
Participant flow — Open Label Extension Phase
MilestoneBIC + F/TAFDTG + F/TAF
Started6230
Completed5429
Not completed81
Withdrew: Protocol violation10
Withdrew: Withdrew consent31
Withdrew: Lost to follow-up40

Outcome measures

PrimaryPercentage of Participants With HIV-1 RNA < 50 Copies/mL as Determined by the FDA-defined Snapshot Algorithm.

The percentage of participants achieving HIV-1 RNA \< 50 copies/mL at Week 24 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.

Time frame:
Week 24
Reported as:
Number · percentage of participants
Percentage of Participants With HIV-1 RNA < 50 Copies/mL as Determined by the FDA-defined Snapshot Algorithm.
percentage of participantsBIC + F/TAFDTG + F/TAF
Percentage of Participants With HIV-1 RNA < 50 Copies/mL as Determined by the FDA-defined Snapshot Algorithm.96.993.9
Statistical analysis
  • BIC + F/TAF vs DTG + F/TAF · Cochran-Mantel-Haenszel · p = 0.5 · Difference in percentages: 2.9 · 95% CI -8.5 to 14.2Cochran-Mantel Haenszel test stratified by baseline HIV-1 RNA stratum (≤ 100,000 copies/mL vs \> 100,000 copies/mL).
SecondaryPercentage of Participants With HIV-1 RNA < 50 Copies/mL as Determined by the FDA-defined Snapshot Algorithm at Week 12

The percentage of participants achieving HIV-1 RNA \< 50 copies/mL at Week 12 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.

Time frame:
Week 12
Reported as:
Number · percentage of participants
Percentage of Participants With HIV-1 RNA < 50 Copies/mL as Determined by the FDA-defined Snapshot Algorithm at Week 12
percentage of participantsBIC + F/TAFDTG + F/TAF
Percentage of Participants With HIV-1 RNA < 50 Copies/mL as Determined by the FDA-defined Snapshot Algorithm at Week 1293.893.9
SecondaryPercentage of Participants With HIV-1 RNA < 50 Copies/mL as Determined by the FDA-defined Snapshot Algorithm at Week 48

The percentage of participants achieving HIV-1 RNA \< 50 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.

Time frame:
Week 48
Reported as:
Number · percentage of participants
Percentage of Participants With HIV-1 RNA < 50 Copies/mL as Determined by the FDA-defined Snapshot Algorithm at Week 48
percentage of participantsBIC + F/TAFDTG + F/TAF
Percentage of Participants With HIV-1 RNA < 50 Copies/mL as Determined by the FDA-defined Snapshot Algorithm at Week 4896.990.9
SecondaryThe Change From Baseline in log10 HIV-1 RNA at Week 12
Time frame:
Baseline; Week 12
Reported as:
Mean · log10 copies/mL
The Change From Baseline in log10 HIV-1 RNA at Week 12
log10 copies/mLBIC + F/TAFDTG + F/TAF
The Change From Baseline in log10 HIV-1 RNA at Week 12-3.03 ± 0.791-3.15 ± 0.731
SecondaryThe Change From Baseline in log10 HIV-1 RNA at Week 24
Time frame:
Baseline; Week 24
Reported as:
Mean · log10 copies/mL
The Change From Baseline in log10 HIV-1 RNA at Week 24
log10 copies/mLBIC + F/TAFDTG + F/TAF
The Change From Baseline in log10 HIV-1 RNA at Week 24-3.09 ± 0.740-3.12 ± 0.757
SecondaryThe Change From Baseline in log10 HIV-1 RNA at Week 48
Time frame:
Baseline; Week 48
Reported as:
Mean · log10 copies/mL
The Change From Baseline in log10 HIV-1 RNA at Week 48
log10 copies/mLBIC + F/TAFDTG + F/TAF
The Change From Baseline in log10 HIV-1 RNA at Week 48-3.09 ± 0.752-3.11 ± 0.852
SecondaryThe Change From Baseline in Cluster of Differentiation 4 Positive (CD4+) Cell Count at Week 12
Time frame:
Baseline; Week 12
Reported as:
Mean · CD4 Cell Count (/μL)
The Change From Baseline in Cluster of Differentiation 4 Positive (CD4+) Cell Count at Week 12
CD4 Cell Count (/μL)BIC + F/TAFDTG + F/TAF
The Change From Baseline in Cluster of Differentiation 4 Positive (CD4+) Cell Count at Week 12170 ± 150.0173 ± 220.5
SecondaryThe Change From Baseline in CD4+ Cell Count at Week 24
Time frame:
Baseline; Week 24
Reported as:
Mean · CD4 Cell Count (/μL)
The Change From Baseline in CD4+ Cell Count at Week 24
CD4 Cell Count (/μL)BIC + F/TAFDTG + F/TAF
The Change From Baseline in CD4+ Cell Count at Week 24190 ± 176.8155 ± 165.8
SecondaryThe Change From Baseline in CD4+ Cell Count at Week 48
Time frame:
Baseline; Week 48
Reported as:
Mean · CD4 Cell Count (/μL)
The Change From Baseline in CD4+ Cell Count at Week 48
CD4 Cell Count (/μL)BIC + F/TAFDTG + F/TAF
The Change From Baseline in CD4+ Cell Count at Week 48258 ± 221.7188 ± 238.7
SecondaryPercentage of Participants With Treatment Emergent Adverse Events (TEAEs) During Double-Blinded Randomized Phase
Time frame:
First dose date up to last dose (maximum duration: 58 Weeks) plus 30 days (During Double-Blinded Randomized Phase)
Reported as:
Number · percentage of participants
Percentage of Participants With Treatment Emergent Adverse Events (TEAEs) During Double-Blinded Randomized Phase
percentage of participantsBIC + F/TAFDTG + F/TAF
Percentage of Participants With Treatment Emergent Adverse Events (TEAEs) During Double-Blinded Randomized Phase87.772.7
SecondaryPercentage of Participants With Treatment Emergent Laboratory Abnormalities During Double-Blind Randomized Phase
Time frame:
First dose date up to last dose (maximum duration: 58 Weeks) plus 30 days (During Double-Blinded Randomized Phase)
Reported as:
Number · percentage of participants
Percentage of Participants With Treatment Emergent Laboratory Abnormalities During Double-Blind Randomized Phase
percentage of participantsBIC + F/TAFDTG + F/TAF
Percentage of Participants With Treatment Emergent Laboratory Abnormalities During Double-Blind Randomized Phase87.587.5
SecondaryPK Parameter: Cmax for Bictegravir (BIC), Emtricitabine (FTC), Tenofovir Alafenamide (TAF) and Tenofavir (TFV) at Steady-State

Cmax is the maximum observed plasma concentration of the drug.

Time frame:
0.5, 1, 1.5, 2, 3, 4, 6, 8, and 24 hours postdose at Week 4 or 8
Reported as:
Mean · ng/mL
PK Parameter: Cmax for Bictegravir (BIC), Emtricitabine (FTC), Tenofovir Alafenamide (TAF) and Tenofavir (TFV) at Steady-State
ng/mLBIC + F/TAFDTG + F/TAF
BIC9344.3 ± 2506.33NA ± NA
FTC1919.1 ± 470.182157.1 ± 486.44
TAF249.1 ± 137.40260.8 ± 212.44
TFV19.1 ± 4.5020.9 ± 8.16
SecondaryPK Parameter: Tmax for BIC, FTC, TAF, and TFV at Steady-State

Tmax was defined as the time to Cmax.

Time frame:
0.5, 1, 1.5, 2, 3, 4, 6, 8, and 24 hours postdose at Week 4 or 8
Reported as:
Median · hours
PK Parameter: Tmax for BIC, FTC, TAF, and TFV at Steady-State
hoursBIC + F/TAFDTG + F/TAF
BIC2.00 (1.50 to 3.00)NA (NA to NA)
FTC1.50 (1.00 to 2.00)1.50 (1.02 to 2.00)
TAF1.00 (0.50 to 1.50)1.00 (0.50 to 1.00)
TFV1.50 (1.50 to 2.00)2.00 (1.53 to 2.00)
SecondaryPK Parameter:Ctau for BIC, FTC and TFV

Ctau was defined as the observed drug concentration at the end of the dosing interval.

Time frame:
0.5, 1, 1.5, 2, 3, 4, 6, 8, and 24 hours postdose at Week 4 or 8
Reported as:
Mean · ng/mL
PK Parameter:Ctau for BIC, FTC and TFV
ng/mLBIC + F/TAFDTG + F/TAF
BIC3508.6 ± 1288.85NA ± NA
FTC76.6 ± 26.35102.6 ± 57.60
TFV10.7 ± 2.6512.2 ± 5.02
SecondaryPK Parameter: AUCtau for BIC, FTC, TAF, and TFV

AUCtau is defined as the area under the concentration-time curve of the drug over time.

Time frame:
0.5, 1, 1.5, 2, 3, 4, 6, 8, and 24 hours postdose at Week 4 or 8
Reported as:
Mean · h*ng/mL
PK Parameter: AUCtau for BIC, FTC, TAF, and TFV
h*ng/mLBIC + F/TAFDTG + F/TAF
BIC139778.8 ± 37810.07NA ± NA
FTC11605.4 ± 3241.8414689.8 ± 5869.37
TAF247.4 ± 140.62245.6 ± 125.03
TFV316.0 ± 74.01369.4 ± 147.96
SecondaryPK Parameter: t1/2 of BIC, FTC, TAF, and TFV

t1/2 was defined as the terminal elimination half-life of the drug

Time frame:
0.5, 1, 1.5, 2, 3, 4, 6, 8, and 24 hours postdose at Week 4 or 8
Reported as:
Median · hours
PK Parameter: t1/2 of BIC, FTC, TAF, and TFV
hoursBIC + F/TAFDTG + F/TAF
BIC16.73 (13.79 to 19.28)NA (NA to NA)
FTC5.46 (5.19 to 6.11)5.70 (5.3 to 6.38)
TAF0.37 (0.28 to 0.49)0.42 (0.40 to 0.45)
TFV37.74 (28.26 to 48.40)34.47 (31.97 to 47.57)

Adverse events

Collected over First dose date to last dose date of BIC + F/TAF or B/F/TAF (maximum duration: 193.4 weeks) plus 30 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
BIC + F/TAF (Double-Blind Randomized)0/65 (0%)4/65 (6.2%)44/65 (67.7%)
DTG + F/TAF (Double Blind Randomized):0/33 (0%)0/33 (0%)18/33 (54.5%)
BIC + F/TAF to B/F/TAF (Open-Label Phase)0/62 (0%)3/62 (4.8%)42/62 (67.7%)
DTG + F/TAF to B/F/TAF (Open-Label Phase)0/30 (0%)5/30 (16.7%)23/30 (76.7%)
Most frequent serious events
Showing 10 of 13
Most frequent serious events
EventBIC + F/TAF (Double-Blind Randomized)DTG + F/TAF (Double Blind Randomized):BIC + F/TAF to B/F/TAF (Open-Label Phase)DTG + F/TAF to B/F/TAF (Open-Label Phase)
Abdominal painGastrointestinal disorders0/650/330/621/30
ColitisGastrointestinal disorders0/650/330/621/30
Diabetic ketoacidosisMetabolism and nutrition disorders1/650/330/621/30
Substance-induced psychotic disorderPsychiatric disorders0/650/330/621/30
Suicide attemptPsychiatric disorders0/650/330/621/30
Bladder massRenal and urinary disorders0/650/330/621/30
PyelonephritisInfections and infestations0/650/331/620/30
Rib fractureInjury, poisoning and procedural complications0/650/331/620/30
Anal cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/650/331/620/30
Umbilical herniaGastrointestinal disorders1/650/330/620/30
Most frequent other events
Showing 10 of 39
Most frequent other events
EventBIC + F/TAF (Double-Blind Randomized)DTG + F/TAF (Double Blind Randomized):BIC + F/TAF to B/F/TAF (Open-Label Phase)DTG + F/TAF to B/F/TAF (Open-Label Phase)
Proctitis gonococcalInfections and infestations1/651/332/625/30
SyphilisInfections and infestations3/651/338/625/30
DiarrhoeaGastrointestinal disorders9/654/334/624/30
CoughRespiratory, thoracic and mediastinal disorders3/651/337/620/30
Upper respiratory tract infectionInfections and infestations7/651/334/621/30
NauseaGastrointestinal disorders5/653/332/623/30
BronchitisInfections and infestations2/650/332/623/30
NasopharyngitisInfections and infestations3/651/333/623/30
Exposure to communicable diseaseInjury, poisoning and procedural complications2/652/336/622/30
HeadacheNervous system disorders6/651/330/621/30

Baseline characteristics

The Safety Analysis Set included participants who were randomized and received at least 1 dose of study drug.

Age, Continuous
Age, Continuous(years)BIC + F/TAFDTG + F/TAFTotal
Mean34 ± 11.438 ± 12.935 ± 12.1
Sex: Female, Male
Sex: Female, Male(Participants)BIC + F/TAFDTG + F/TAFTotal
Female134
Male643094
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)BIC + F/TAFDTG + F/TAFTotal
American Indian or Alaska Native101
Asian123
Black241236
Native Hawaiian or Pacific Islander101
White381856
Other011
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)BIC + F/TAFDTG + F/TAFTotal
Hispanic or Latino11415
Not Hispanic or Latino542983
HIV-1 RNA
HIV-1 RNA(log10 copies/mL)BIC + F/TAFDTG + F/TAFTotal
Mean4.39 ± 0.7644.38 ± 0.8664.39 ± 0.795
HIV-1 RNA category
HIV-1 RNA category(Participants)BIC + F/TAFDTG + F/TAFTotal
≤ 100,000 copies/mL552681
> 100,000 to ≤ 400,000 copies/mL6612
> 400,000 copies/mL415
CD4 Cell Count
CD4 Cell Count(cells/μL)BIC + F/TAFDTG + F/TAFTotal
Mean471 ± 190.9507 ± 271.0483 ± 220.3
CD4 Cell Count Category
CD4 Cell Count Category(Participants)BIC + F/TAFDTG + F/TAFTotal
< 200 cells/μL336
≥ 200 to < 350 cells/µL17825
≥ 350 to < 500 cells/µL20626
≥ 500 cells/µL251641
08

Study locations

21 sites
  • Phoenix, Arizona 85012, United States
  • Los Angeles, California 90036, United States
  • Los Angeles, California 90069, United States
  • Sacramento, California 95817, United States
  • Washington, District of Columbia 20009, United States
  • Washington, District of Columbia 20036, United States
  • Fort Lauderdale, Florida 33316, United States
  • Orlando, Florida 32803, United States
  • West Palm Beach, Florida 33401, United States
  • Atlanta, Georgia 30312, United States
  • Decatur, Georgia 30033, United States
  • Boston, Massachusetts 02115, United States
  • Berkley, Michigan 48072, United States
  • Newark, New Jersey 07102, United States
  • Austin, Texas 78705, United States
  • Dallas, Texas 75208, United States
  • Houston, Texas 77004, United States
  • Houston, Texas 77098, United States
  • Longview, Texas 75605, United States
  • Annandale, Virginia 22003, United States
  • Seattle, Washington 98104, United States
09

References and documents

Publications

  • Sax PE, DeJesus E, Crofoot G, Ward D, Benson P, Dretler R, Mills A, Brinson C, Peloquin J, Wei X, White K, Cheng A, Martin H, Quirk E. Bictegravir versus dolutegravir, each with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection: a randomised, double-blind, phase 2 trial. Lancet HIV. 2017 Apr;4(4):e154-e160. doi: 10.1016/S2352-3018(17)30016-4. Epub 2017 Feb 15. PubMed 28219610 ↗
  • Sax PE, DeJesus E, Crofoot G, Ward D, Benson P, Dretler R, Mills A, Brinson C, Wei X, Collins SE, Cheng A. Coformulated bictegravir, emtricitabine, tenofovir alafenamide after initial treatment with bictegravir or dolutegravir and emtricitabine/tenofovir alafenamide. AIDS. 2018 Jul 31;32(12):1723-1725. doi: 10.1097/QAD.0000000000001894. PubMed 29794828 ↗

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2015 to primary completion in Nov 2015, 8 months.

Results were first posted in Mar 2018, 2 years 3 months after primary completion. A results delay was requested in Aug 2016.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 20, 2015
First posted
Mar 25, 2015
StartActual
Mar 23, 2015
Primary completionActual
Nov 30, 2015
CompletionActual
Feb 27, 2019
Results delay requested
Aug 22, 2016
Results first posted
Mar 27, 2018
Last update
Apr 7, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 7, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02397694
Lead sponsor
Gilead Sciences
Responsible party
Sponsor
First posted
Mar 25, 2015
Start date
Mar 23, 2015
Primary completion
Nov 30, 2015
Completion
Feb 27, 2019
Results posted
Mar 27, 2018
Last update
Apr 7, 2020

Study contacts

Gilead Study Director
study director · Gilead Sciences

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Bictegravir · Emtricitabine · Tenofovir alafenamide

Start the discussion